text_1: 纳武利 尤 单抗 + 伊匹 单抗 组和 化疗 组 的 客观 缓解 率 分别 为 35.9% ( 95% CI , 31.1 ~ 40.8 ) ( 5.8% 的 患者 完全缓解 ) 和 30.0% ( 95% CI , 25.5 ~ 34.7 ) ( 1.8% 的 患者 完全缓解 ) ( 表 S9 ) .
  
text_2: the objective response rate was 35.9 % ( 95 % CI , 31.1 to 40.8 ) with nivolumab plus ipilimumab ( with 5.8 % of patients having a complete response ) versus 30.0 % ( 95 % CI , 25.5 to 34.7 ) with chemotherapy ( with 1.8 % of patients having a complete response ) ( Table S9 ) .
  